BRCA1 and neoplasm: In ARIEL3, improvement of PFS of rucaparib vs. placebo was observed in all subgroups of patients: in BRCA1/2-mutated (deleterious germline or somatic) (16.6 months vs. 5.4 months), in patients with HRD tumor (defined as g/sBRCA1/2-mutated or wtBRCA1/2 with high LOH) (13.6 months vs. 5.4 months), and in the intention-to-treat population (10.8 months vs. 5.4 months) (26).